Following a settlement over Merck's $700 million claims over NotPetya damages, questions remain about what constitutes an act of war for cyber-insurance policies.
EconoTimes is a fast growing non-partisan source of news and intelligence on global economy and financial markets, providing timely, relevant, and critical insights for market professionals and those who want to make informed investment decisions.
Drugmaker Merck will pay Daiichi Sankyo $5.5-billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to…
Merck agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of its candidate cancer drugs, in a deal that could be worth up to $22 billion depending on the treatments' success.
Merck says court ruled in its favor over patent-infringement suit marketwatch.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketwatch.com Daily Mail and Mail on Sunday newspapers.